Announced details
Fuji Pharma Co., Ltd. and Gedeon Richter Plc entered into a joint development agreement as part of their strategic collaboration. FimmCyte developed FMC2. Gedeon Richter Plc acquired the drug discovery portfolio from Celmatix.
Gedeon Richter Plc is headquartered in Hungary and was founded in 1901. Its market capitalization in 2025 was €4.8 billion and its sales were €2.3 billion. It operates the largest research and development center in Central Europe. FimmCyte is a Swiss biotechnology company established in 2022 as a spin-off from the University of Zurich and University Hospital Zurich. Celmatix is a preclinical-stage women’s health biotechnology company established in 2009.
Gedeon Richter Plc: Hungary. FimmCyte: Switzerland. Fuji Pharma Co., Ltd.: Chiyoda-ku, Tokyo.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Investment in the development of new treatments for women’s healthcare is estimated to account for less than 5% of the pharmaceutical industry overall.
| Item | Details |
|---|---|
| Names of Products / Services Covered | FMC2 (antibody), Women’s health drug discovery portfolio, including an oral agonist acting on the FSH receptor, JNK inhibitor, Therapeutic antibody targeting AMH |
| Counterparty | Gedeon Richter Plc. (Gedeon Richter Plc.), FimmCyte, Celmatix |
| Counterparty overview | Gedeon Richter Plc is headquartered in Hungary and was founded in 1901. Its market capitalization in 2025 was €4.8 billion and its sales were €2.3 billion. It operates the largest research and development center in Central Europe. FimmCyte is a Swiss biotechnology company established in 2022 as a spin-off from the University of Zurich and University Hospital Zurich. Celmatix is a preclinical-stage women’s health biotechnology company established in 2009. |
| Relationship with the Company | Fuji Pharma Co., Ltd. and Gedeon Richter Plc entered into a joint development agreement as part of their strategic collaboration. FimmCyte developed FMC2. Gedeon Richter Plc acquired the drug discovery portfolio from Celmatix. |
| Contract Date | 24 March 2026 (the date the agreement was announced; the agreement date itself was not specified) |
| Applicable area | Women’s healthcare, Gynecology, Endometriosis treatment, Fertility treatment, Ovarian stimulation, Management of pain and inflammation |
| Location | Gedeon Richter Plc: Hungary. FimmCyte: Switzerland. Fuji Pharma Co., Ltd.: Chiyoda-ku, Tokyo. |
| Location scale | Gedeon Richter Plc operates the largest research and development center in Central Europe. |
| Source | Investment in the development of new treatments for women’s healthcare is estimated to account for less than 5% of the pharmaceutical industry overall. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen business development and research and development in gynecology, a priority strategic area for both companies, and enhance Fuji Pharma Co., Ltd.’s expertise and ability to execute its strategy in women’s healthcare.